Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 168 for:    pertuzumab

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (PETRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01805908
Recruitment Status : Terminated (Accrual is very poor)
First Posted : March 6, 2013
Last Update Posted : June 6, 2016
Sponsor:
Information provided by (Responsible Party):
Ontario Clinical Oncology Group (OCOG)

Brief Summary:
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body Single Photon Emission Computed Tomography (SPECT) imaging to predict who will respond to treatment with Trastuzumab.

Condition or disease Intervention/treatment Phase
Breast Cancer Other: 111In-Pertuzumab + SPECT-CT Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer
Study Start Date : November 2013
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 111In-Pertuzumab + SPECT-CT
Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
Other: 111In-Pertuzumab + SPECT-CT
111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.




Primary Outcome Measures :
  1. Change in tumour SUV (Standardized Uptake Value) from baseline to Day 8. [ Time Frame: 8 days ]
    The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 8 (Day 8 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.

  2. Safety attributable to 111In-Pertuzumab injections [ Time Frame: 3 months ]
    The safety, i.e. toxicities, attributable to 111In-Pertuzumab injections will be evaluated using the National Cancer Institute (NCI) Common Termination for Adverse Events Version 4.


Secondary Outcome Measures :
  1. Pharmacokinetics (PK) and tumour and normal tissue localization properties of 111In-PmAb will be measured. [ Time Frame: 3 months ]
    The pharmacokinetics of 111In-PmAb and tumour and normal tissue localization properties of 111In-PmAb will be measured. Standard PK parameters (t1/2 alpha, t1/2β, V1, Vss and CL) will be calculated.

  2. Optimal mass dose of 111In-PmAb [ Time Frame: 3 months ]
    The dose of 111In-PmAb that is associated with the optimal SPECT-CT images will be established.

  3. Change in tumour SUV from Baseline to Day 36 [ Time Frame: 3 months ]
    The imaging outcome for exploring the association between imaging and clinical outcome is the percent change in tumour SUV from baseline to Day 36 (Day 36 SUV - baseline SUV) /baseline SUV times 100%. The Positron Emission Tomography Evaluation Response Criteria In Solid Tumours (PERCIST) criterion will be used to measure SUV change.

  4. Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria. [ Time Frame: 3 months ]
    Clinical response (complete or partial) to treatment will be measured using Response Evaluation Criteria In Solid Tumours (RECIST) criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Metastatic, locally recurrent (local recurrence not amenable to surgical resection of curative intent), or locally advanced (T3 or T4, any N, M0) adenocarcinoma of the breast.
  2. Tumour HER2 positive by immunohistochemistry for HER2 protein over-expression or by Fluorescence in situ Hybridization (FISH) for HER2 gene amplification, as defined by American Society of Clinical Oncology/College of American Pathologists guidelines
  3. Initiating treatment with TmAb
  4. Clinically measurable disease (by RECIST for patients with metastatic disease).

Exclusion Criteria:

  1. Male gender.
  2. Less than 18 years of age.
  3. Life expectancy < 12 weeks.
  4. Only site of metastases is liver.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of > 2.
  6. Currently receiving PmAb or lapatinib for treatment of MBC.
  7. Having received TmAb as adjuvant therapy within the previous 6 months.
  8. Required to receive another radiopharmaceutical during the first week of the study.
  9. Hypersensitivity to monoclonal antibodies.
  10. Left Ventricular Ejection Fraction (LVEF) < 50% at baseline (within 42 days of study registration) as determined by either echocardiogram (ECHO) or Multi-Gated Acquisition (MUGA) scan.
  11. Hematology and/or biochemistry parameters outside acceptable ranges:

    • absolute neutrophil count <1,500 cells/mm3,
    • platelet count <100,000 cells/mm3,
    • hemoglobin <9 g/dL,
    • total bilirubin > upper limit of normal (ULN) (unless subject has documented Gilbert's Syndrome),
    • aspartate aminotransferase (AST) [serum glutamic oxaloacetic transaminase(SGOT)] and alanine aminotransferase (ALT) [serum glutamic pyruvate transaminase(SGPT)] >2.5 × ULN,
    • serum creatinine >2.0 mg/dL or 177 μmol/L,
    • alanine aminotransferase (ALP) >2.5 x ULN.
  12. Known pregnancy or lactating female (e.g. positive serum beta-human chorionic gonadotropin (B-hCG) pregnancy test).
  13. For women of childbearing potential, failure to agree to use a highly effective form of contraception (patient and/or partner, e.g., surgical sterilization) or two effective forms of contraception (a reliable barrier method in conjunction with spermicidal jelly, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of study treatment.
  14. Any condition, which in the investigator's opinion would not make the patient a suitable candidate for inclusion in the trial.
  15. Participation in another clinical trial.
  16. Inability to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01805908


Locations
Layout table for location information
Canada, Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Investigators
Layout table for investigator information
Principal Investigator: Mark Levine Ontario Clinical Oncology Group, McMaster University
Principal Investigator: Raymond Reilly University of Toronto
Principal Investigator: Kathleen Pritchard Ontario Clinical Oncology Group (OCOG)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier: NCT01805908     History of Changes
Other Study ID Numbers: OCOG-2011-PETRA
First Posted: March 6, 2013    Key Record Dates
Last Update Posted: June 6, 2016
Last Verified: June 2016

Keywords provided by Ontario Clinical Oncology Group (OCOG):
metastatic
breast cancer
herceptin
imaging
tumour response
adenocarcinoma
SPECT-CT
pertuzumab
trastuzumab
locally advanced

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Trastuzumab
Pertuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents